Drugs / Icapamespib
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04782609 | Dec 2021 → Nov 2022 | IDH-wildtype anaplastic astrocytoma, glioblastoma | Samus Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT03935568 | Jun → Dec 2019 | Alzheimer disease | Samus Therapeutics, Inc. | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Icapamespib | “Safety, Tolerability and Pharmacokinetics of Icapamespib, a Selective Epichaperome Inhibitor, in Healthy Adults.” PMID 36281667 ↗ 2022 |
| Known as | PU-HZ151 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650317 ↗ |
| Modality | Small molecule | “icapamespib, a purine scaffold inhibitor of epichaperomes” PMID 36281667 ↗ 2022 |
| Route | Oral | “oral single doses (10, 20, and 30 mg icapamespib or placebo) were administered” PMID 36281667 ↗ 2022 |